News

DPR Construction Again Named One of the Nation’s Best Places to Work by U.S. News & World Report

DPR Construction, one of the nation’s top technical builders, was named one of its Best Companies to Work For: Private Companies and one of the Best Companies to Work For: Engineering and Construction for the second consecutive year by U.S. News & World Report, the global authority in rankings and consumer advice.

“DPR has been focused on taking care of people since day one,” said George Pfeffer, DPR Construction CEO and Leadership Team member. “For the last 35 years, we’ve continuously evolved how we do that, but the goal has remained the same: make sure that the people we rely on to help us build great things know that we want DPR to the be place that they grow, develop and build a great career.”

Creating a culture of belonging is a top priority for DPR, which follows a shared leadership model. It also invests in supporting its team’s mental wellbeing, not only designing and tailoring internal programs but also collaborating with leading mental health organizations, like Mental Health America, which recently awarded the company a Gold Bell Seal for Workplace Mental Health.

“We want everyone on our team to feel energized coming to work and comfortable sharing their ideas,” Pfeffer added. “Our success depends on the contributions and innovations of all of our teammates, so we work hard to ensure everyone understands that they are respected and empowered to speak up.”

In addition to providing competitive compensation, DPR offers industry-leading benefits to its team, including those in the skilled trades. Those include not only traditional benefits, like health and life insurance, but also additional offerings (which vary depending on tenure and union affiliation) like holiday pay, financial assistance for education expenses, free access to counseling, family planning assistance and more.

U.S. News’ Best Companies to Work For ratings reflect the ever-changing sentiments impacting employee decision-making when evaluating the “best” company for them. These sentiments are examined using factors that include quality of pay and benefits, work-life balance and flexibility, job and company stability, physical and psychological comfort, belongingness and esteem, and career opportunities and professional development.

The Best Companies to Work For: Private Companies list features the top 277 companies out of 1,094 businesses evaluated across 14 industries. To calculate the ratings, U.S. News only considered privately owned companies with at least 5,000 employees that had at least 75 Glassdoor reviews written between 2021 and 2024. Developed with insights from a panel of six experts, the methodology also factors in data, including employee sentiment and regulatory enforcement data, gathered from U.S. News’ partners Revelio Labs and Good Jobs First.

In addition to this recognition from U.S. News, DPR has also recently been named a Fast Company Best Workplace for Innovators and one of America’s Best Employers by Forbes. Newsweek has recognized DPR as one of America’s Greatest Employers overall and for Mental Wellbeing and Diversity. DPR has also been recognized by its employees as a best place to work in more than 15 U.S. cities in the last year.

People interested in working at DPR can explore benefits and current job openings on DPR’s website.

 

Ready more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation